-->

Tag: accelerated approval myeloma drugs

Home / accelerated approval myeloma drugs

Categories

Elranatamab-bcmm receives accelerated approval by FDA for multiple myeloma

Nov 2023: Elranatamab-bcmm (Elrexfio, Pfizer, Inc.) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager that was given accelerated approval by the Food and Drug Administratio...
accelerated-approval-myeloma-drugs

Talquetamab-tgvs has received accelerated approval for relapsed or refractory multiple myeloma

August 2023: Talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) has been given accelerated approval by the Food and Drug Administration for the treatment of adults with relapsed or refractory multiple ...
accelerated-approval-myeloma-drugs

Scan the code